95689-38-6

Usage

Uses

Used in Pharmaceutical Industry:
2-[3-(DIMETHYLAMINO)-1-METHOXY-2-PROPENYLIDENE]MALONONITRILE is used as a key intermediate in the synthesis of antitumor agents for the pharmaceutical industry. Its role in the production of Gimeracil (G378000) highlights its importance in contributing to the development of cancer treatment options.
As an intermediate in the synthesis of Gimeracil, 2-[3-(DIMETHYLAMINO)-1-METHOXY-2-PROPENYLIDENE]MALONONITRILE plays a crucial role in the pharmaceutical industry, where it is utilized to create effective antitumor agents that can potentially improve the lives of cancer patients. Its chemical properties and orange solid form make it a distinctive and valuable component in the synthesis process.

InChI:InChI=1/C9H11N3O/c1-12(2)5-4-9(13-3)8(6-10)7-11/h4-5H,1-3H3/p+1/b5-4+

Upstream product

• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 5417-82-3 (1-ethoxyethylidene)malononitrile 
• 67-56-1 methanol 
• 78-39-7 Triethyl orthoacetate 
• 109-77-3 malononitrile 
• 5515-16-2 2-(methoxyethylidene)propanedinitrile 

Downstream Products

• 74133-20-3 4-methoxypyridine-3-carbonitrile 
• 626-03-9 4-hydroxy-2-pyridone 
• 609-70-1 4-hydroxynicotinic acid 
• 635731-97-4 2-Brom-3-cyan-4(1H)-pyridon 
• 147619-40-7 5-chloro-3-cyano-4-methoxy-2(1H)-pyridinone 
• 1097202-33-9 (3-amino-4-methoxythieno[2,3-b]pyridin-2-yl)(phenyl)methanone 
• 1097202-32-8 (3-amino-4-methoxythieno[2,3-b]pyridin-2-yl)(4-(4-fluorophenyl)piperazin-1-yl)methanone 
• 338773-61-8 ethyl 3-amino-4-methoxythieno[2,3-b]pyridine-2-carboxylate 
• 1097202-27-1 2-(2-oxo-2-(4-phenylpiperazin-1-yl)ethylthio)-4-methoxypyridine-3-carbonitrile 
• 1097202-26-0 3-(4-chlorophenyl)-9-methoxypyrido[3',2':4,5]thieno[3,2-d][1,2,3]triazin-4(3H)-one 
• 1097202-23-7 3-amino-N-(4-chlorophenyl)-4-methoxythieno[2,3-b]pyridine-2-carboxamide 
• 21642-98-8 2-hydroxy-4-methoxypyridine-3-carbonitrile 
• 98645-45-5 2-Chlor-4-ethoxypyridin-3-carbonitril 
• 902171-53-3 1,4-dihydro-1,2-dimethyl-4-oxo-nicotinic acid 

Relevant academic research and scientific papers

DIVALENT NUCLEOBASE COMPOUNDS AND USES THEREFOR

Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (?PNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.

Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors

We have previously reported a nanomolar inhibitor of antiapoptotic Mcl-1 protein, 3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1). S1 plays its function by binding to the BH3 groove of Mcl-1. Basing on this spacial structural characteristic, we developed a novel class of Mcl-1 inhibitor using fragment-based drug discovery approach. By dissecting S1, we identified the compound 4 with a 2-hydroxypyridine core as the starting fragment. In the following molecular growth, we used the ligand efficiency evaluation and fit quality score to assess the fragments. A novel potent compound, N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide (12c), which binds Mcl-1 with an IC50 value of 54 nM was obtained. Compound 12c demonstrated a better aqueous solubility than S1.

INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel indole and benzoxazine derivatives which are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2") and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

Tricyclic thienopyridine-pyrimidones/thienopyrimidine-pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain

Introduction of small unsaturated alkylamino groups at the 4-position of the A-ring of the tricyclic framework (triazafluorenone) afforded extremely potent and selective mGluR1 antagonists with desirable properties. Compounds 11q and 11s are active in the

IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

ANTAGONISTS OF THE MGLU RECEPTOR AND USES THEREOF

The present invention discloses compounds of general formula (I) wherein X1-X4 and R1-R3 are as defined in the description. The present invention also discloses methods of treatment for pain, neurodegeneration and convulsive states in a host mammal in need thereof, and pharmaceutical compositions including those compounds.

Synthesis of 1,4-dihydro-2-methyl-4-oxo-nicotinic acid: Ochiai's route failed

The synthesis of 1,4-dihydro-2-methyl- and 1,4-dihydro-1,2-dimethyl-4-oxo-nicotinic acids was accomplished following a route other than Ochiai's procedure, which yielded the isomer 1,6-dihydro-2-methyl-6-oxo-nicotinic acid ethyl ester, and not the 4-oxo-derivative, as reported. Analytical data confirmed the identity of the two isomer oxo-nicotinic acids. UV-vis and potentiometric preliminary data showed that Al(III) does not form complexes with 1,6-dihydro-2-methyl-6-oxo-nicotinic acid ethyl ester in solution, as expected, but with 1,4-dihydro-2-methyl-4-oxo-nicotinic acid.